Majority of prostate cancer (PCa) patients carry TMPRSS2/ERG (T/E) fusion genes and there has been tremendous interest in understanding how the T/E fusion may promote progression of PCa. This evidence concerns the gene TMPRSS2 and posterior cortical atrophy.